Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study

Psychopharmacology

Volumn 233, Issue 23-24, 2016, Pages 3947-3952

  Morlán Coarasa, María José ^a   Arias Loste, María Teresa ^a   Ortiz García de la Foz, Víctor ^b   Martínez García, Obdulia ^b   Alonso Martín, Carmen ^a   Crespo, Javier ^a   Romero Gómez, Manuel ^c   Fábrega, Emilio ^a   Crespo Facorro, Benedicto ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Antipsychotics; Cardiometabolic risk; Hepatic steatosis; Lipids; Metabolic syndrome; Psychosis

Indexed keywords

ARIPIPRAZOLE; HIGH DENSITY LIPOPROTEIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SURVIVAL RATE; WAIST CIRCUMFERENCE; COMPLICATION; MIDDLE AGED; PSYCHOSIS; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; FEMALE; HUMANS; INCIDENCE; MALE; METABOLIC DISEASES; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 84987638637     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4422-7     Document Type: Article

References (16)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
2. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854
3. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140
5. Caseiro O, Perez-Iglesias R, Mata I, Martinez-Garcia O, Pelayo-Teran JM, Tabares-Seisdedos R, et al. (2012) Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 46:1099–1105
6. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71:1350–1363
7. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126
8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402
9. Foley DL, Morley KI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68:609–616
10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752
11. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071
12. Liu H, Nonalcoholic LHY (2014) Fatty liver disease and cardiovascular disease. World J Gastroenterol 20:8407–8415
13. Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, et al. (2014) Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 17:41–51
14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325
15. Targher G (2007) Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 24:1–6
16. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350